Latest Insider Transactions at Nkarta, Inc. (NKTX)
This section provides a real-time view of insider transactions for Nkarta, Inc. (NKTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Nkarta, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Nkarta, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 01
2021
|
Nadir Mahmood President |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+9.39%
|
$10,500
$3.89 P/Share
|
|
Jun 21
2021
|
Paul J Hastings Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
8,500
-1.82%
|
$221,000
$26.64 P/Share
|
|
Jun 16
2021
|
Nadir Mahmood President |
BUY
Exercise of conversion of derivative security
|
Direct |
1,800
+5.61%
|
$5,400
$3.89 P/Share
|
|
Jun 02
2021
|
Ralph Brandenberger Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
4,140
-100.0%
|
$99,360
$24.5 P/Share
|
|
Jun 02
2021
|
Ralph Brandenberger Chief Technical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,140
+39.36%
|
$12,420
$3.24 P/Share
|
|
May 10
2021
|
Nadir Mahmood President |
SELL
Open market or private sale
|
Direct |
3,000
-9.53%
|
$81,000
$27.16 P/Share
|
|
May 03
2021
|
James Trager Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,600
-3.78%
|
$111,600
$31.64 P/Share
|
|
May 03
2021
|
James Trager Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,250
+4.48%
|
$6,750
$3.89 P/Share
|
|
Apr 01
2021
|
Ra Capital Management, L.P. |
BUY
Other acquisition or disposition
|
Indirect |
568,033
+28.14%
|
$18,177,056
$32.9 P/Share
|
|
Apr 01
2021
|
Nadir Mahmood President |
SELL
Open market or private sale
|
Direct |
3,500
-10.0%
|
$112,000
$32.7 P/Share
|
|
Apr 01
2021
|
Nadir Mahmood President |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+9.09%
|
$10,500
$3.89 P/Share
|
|
Mar 30
2021
|
Paul J Hastings Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
17,000
-2.28%
|
$527,000
$31.23 P/Share
|
|
Feb 02
2021
|
James Trager Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,800
-5.61%
|
$112,000
$40.0 P/Share
|
|
Feb 02
2021
|
James Trager Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,800
+5.32%
|
$50,400
$18.0 P/Share
|
|
Feb 01
2021
|
James Trager Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,600
-3.62%
|
$136,800
$38.76 P/Share
|
|
Feb 01
2021
|
James Trager Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,250
+4.25%
|
$6,750
$3.89 P/Share
|
|
Jan 25
2021
|
Nadir Mahmood President |
SELL
Open market or private sale
|
Direct |
5,500
-7.71%
|
$264,000
$48.63 P/Share
|
|
Jan 25
2021
|
Nadir Mahmood President |
BUY
Exercise of conversion of derivative security
|
Direct |
5,500
+12.94%
|
$16,500
$3.89 P/Share
|
|
Jan 14
2021
|
Nadir Mahmood President |
BUY
Exercise of conversion of derivative security
|
Direct |
3,083
+8.92%
|
$9,249
$3.89 P/Share
|
|
Dec 03
2020
|
Nadir Mahmood President |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+9.55%
|
$9,000
$3.89 P/Share
|
|
Jul 14
2020
|
Novo Holdings > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
555,555
+16.59%
|
$9,999,990
$18.0 P/Share
|
|
Jul 14
2020
|
Novo Holdings > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,238,310
+50.0%
|
-
|
|
Jul 14
2020
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
3,333,333
+37.29%
|
$59,999,994
$18.0 P/Share
|
|
Jul 14
2020
|
Ra Capital Management, L.P. |
BUY
Conversion of derivative security
|
Indirect |
2,271,796
+50.0%
|
-
|
|
Jul 14
2020
|
Glaxosmithkline PLC Director |
BUY
Open market or private purchase
|
Indirect |
833,333
+20.92%
|
$14,999,994
$18.0 P/Share
|
|
Jul 14
2020
|
Glaxosmithkline PLC Director |
BUY
Conversion of derivative security
|
Indirect |
2,317,399
+46.33%
|
-
|
|
Jul 14
2020
|
James E Flynn > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,000,000
+29.24%
|
$18,000,000
$18.0 P/Share
|
|
Jul 14
2020
|
James E Flynn > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,419,872
+50.0%
|
-
|